Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Average Price Target of $87.38 According to Analysts

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $91.29.

A number of equities analysts have recently commented on the stock. Citigroup increased their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Canaccord Genuity Group upped their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Finally, The Goldman Sachs Group upped their price target on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th.

Kiniksa Pharmaceuticals International Stock Down 0.5%

Shares of NASDAQ:KNSA opened at $75.73 on Friday. The firm has a market cap of $5.91 billion, a price-to-earnings ratio of 78.07 and a beta of 0.09. Kiniksa Pharmaceuticals International has a 12 month low of $35.20 and a 12 month high of $82.94. The company’s fifty day simple moving average is $76.56 and its 200 day simple moving average is $61.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The firm had revenue of $243.60 million for the quarter, compared to the consensus estimate of $226.49 million. Research analysts expect that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 4,600 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total value of $369,380.00. Following the sale, the chief accounting officer owned 29,062 shares in the company, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the sale, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. This represents a 23.94% decrease in their position. The SEC filing for this sale provides additional information. 51.98% of the stock is currently owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds have recently modified their holdings of the stock. Inspire Investing LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at approximately $1,698,000. BNP Paribas Financial Markets boosted its stake in Kiniksa Pharmaceuticals International by 27.3% in the 4th quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock valued at $34,311,000 after purchasing an additional 178,366 shares during the period. OMERS ADMINISTRATION Corp bought a new stake in Kiniksa Pharmaceuticals International in the 1st quarter valued at $631,000. Headlands Technologies LLC acquired a new position in Kiniksa Pharmaceuticals International in the 2nd quarter valued at $1,161,000. Finally, SG Americas Securities LLC grew its holdings in Kiniksa Pharmaceuticals International by 18.2% in the 1st quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock valued at $30,825,000 after buying an additional 98,783 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for patients with debilitating diseases, particularly conditions involving the immune system and inflammation. The company concentrates on areas of significant unmet medical need and uses biologic medicines and other targeted approaches in its research and development programs.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor.